Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib and Nivolumab in Recurrent or Refractory Hepatocellular Carcinoma
NCT06354387Phase 1Completed
- Sponsor
- China Medical University Hospital
- Start
- Feb 2022
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alectinib and nivolumab in hepatocellular carcinoma (HCC), sponsored by China Medical University Hospital. Primary endpoint: Objective Response Rate at 52 weeks. Started Feb 2022; status: completed.
02
Drugs
alectinibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06354387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354387.